<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32392516</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1488-2329</ISSN><JournalIssue CitedMedium="Internet"><Volume>192</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title><ISOAbbreviation>CMAJ</ISOAbbreviation></Journal><ArticleTitle>Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.</ArticleTitle><Pagination><StartPage>E319</StartPage><EndPage>E320</EndPage><MedlinePgn>E319-E320</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1503/cmaj.191236</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Breiner</LastName><ForeName>Ari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner, Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology (Zinman), Department of Medicine, University of Toronto, Toronto, Ont. abreiner@toh.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner, Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourque</LastName><ForeName>Pierre R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner, Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>CMAJ</MedlineTA><NlmUniqueID>9711805</NlmUniqueID><ISSNLinking>0820-3946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057176" MajorTopicYN="N">Compassionate Use Trials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000600" MajorTopicYN="Y">supply &amp; distribution</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005380" MajorTopicYN="N">Financing, Government</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000600" MajorTopicYN="Y">supply &amp; distribution</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000600" MajorTopicYN="Y">supply &amp; distribution</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: Ari Breiner has served as site principal investigator for trials for amyotrophic lateral sclerosis funded by Mallinkrodt, Cytokinetics and the University of Calgary. He has also received research grant funding from CIDP/GBS Foundation International, Grifols and Muscular Dystropy Canada, and honoraria from CSL, Allergan, Pfizer and Akcea. Ari Breiner and Lorne Zinman have received honoraria from Mitsubishi Tanabe Pharma. Lorne Zinman has also received an honorarium from Biogen. No other competing interests were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32392516</ArticleId><ArticleId IdType="pmc">PMC7101182</ArticleId><ArticleId IdType="doi">10.1503/cmaj.191236</ArticleId><ArticleId IdType="pii">192/12/E319</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12715790</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Edaravone ALS Study Group. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:610&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>CADTH Common Drug Review: pharmacoeconomic review report. Edaravone (Radicava) (Mitsubishi Tanabe Pharma Corporation): Indication &#x2014; for the treatment of amyotrophic lateral sclerosis (ALS). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019.</Citation></Reference><Reference><Citation>Curwin L. Terri Bishop is living with ALS but still embraces the good in each day. Truro News 2018. May 25.</Citation></Reference><Reference><Citation>Food and Drugs Act (R.S.C., 1985, c. F-27). Available: https://laws-lois.justice.gc.ca/eng/acts/f-27/ (accessed 2020 Mar. 2).</Citation></Reference><Reference><Citation>Laucius J.
&#x2018;I&#x2019;m going to die anyway&#x2019;: Should terminally ill patients in Canada get &#x2018;the right to try&#x2019;?
Ottawa Citizen
2016. 
December
2
Available: https://ottawacitizen.com/news/national/should-dying-patients-have-the-right-to-try-unapproved-drugs-a-battle-is-brewing (accessed 2020 Mar. 2).</Citation></Reference><Reference><Citation>Access to therapies: Radicava (edaravone) update. Toronto: Amyotrophic Lateral Sclerosis Society of Canada; 2019. 
Available: www.als.ca/blogs/access-to-therapies-radicava-edaravone-update/ (accessed 2020 Feb. 19).</Citation></Reference><Reference><Citation>CADTH Canadian drug expert committee recommendation: Edaravone (Radicava &#x2014; Mitsubishi Tanabe Pharma Corporation) &#x2014; indication: for the treatment of amyotrophic lateral sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>